Most of the technological developments that have dramatically changed the cardiovascular device market are the result of innovation by small companies that were able to grow along with their products' successes. More recently, however, the device landscape has changed, especially for cardiovascular companies, primarily with large companies dominating distribution channels, making it tougher for small companies to bring products to market. By identifying an unmet clinical need in interventional cardiology and maintaining a competitive head start, PercuSurge is looking to turn the clock back to the days when a small company could carve out its own niche in this huge market.
by Stephen Levin
When Peter Rule, fresh from his success as president of infusion pump-maker MiniMed Inc. , one of the most successful device IPOs of 1995 [See Deal], took over the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.